| Date | Title | Description | Source |
| 04.03.2024 | QurAlis to Present Data That Show its Splice-Switching ASOs ... | UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical... | svhealthin... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia... | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital fl... | fiercebiot... |
| 06.04.2023 | QurAlis Announces First Patient Dosed With QRL-201, a First-... | First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a t... | svhealthin... |
| 04.04.2023 | Latest Updates of 6 Viva's Portfolio Companies | HONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innova... | en.prnasia... |
| 10.03.2023 | QurAlis Closes $88 Million Series B |
CAMBRIDGE, MA, QurAlis Corporation, a clinical-stage biotechnology company, has closed an oversubs... | vcnewsdail... |
| 09.03.2023 | QurAlis Closes $88M Series B Financing | QurAlis, a Cambridge, MA-based clinical-stage biotechnology company, raised $88M in Series B funding... | finsmes.co... |
| 09.03.2023 | ALS biotech QurAlis gets $88M boost from four pharmas for pa... | QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the... | svhealthin... |
| 09.03.2023 | QurAlis Closes $88 Million Series B Financing to Advance Pre... | EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round | svhealthin... |
| 09.03.2023 | QurAlis Closes $88 Million Series B to Advance Precision Med... | - | dolbyventu... |
| 05.01.2023 | QurAlis Announces First-in-Human Dose in Phase 1 Clinical Tr... | QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration | svhealthin... |
| 27.07.2022 | Portfolio Highlights: Clinical and Financing Updates of AIxp... | SHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioI... | en.prnasia... |
| 21.06.2022 | QurAlis Announces the Appointment of Anne C. Whitaker as Cha... | Industry veteran brings proven track record in building successful businesses and leading high-perfo... | svhealthin... |
| 26.05.2022 | Portfolio Highlights: Clinical and Financing Updates of Anji... | SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator... | en.prnasia... |
| 29.01.2022 | ZK International : Announces Record Revenues of $99.41 Milli... | ZK International Group Co., Ltd. Announces Record Revenues of $99.41 Million, an Increase of 14.5% f... | marketscre... |
| 14.09.2021 | QurAlis Announces Development Candidate for ALS Targeting ST... | QRL-201 is a first-in-class molecule that rescues STATHMIN-2 loss of function in motor neuron diseas... | svhealthin... |
| 14.09.2021 | QurAlis Announces Development Candidate for ALS Targeting ST... | | prnewswire... |
| 01.07.2020 | QurAlis Announces Agreement to Strengthen ALS Pipeline | Cambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused on developing precisio... | svhealthin... |
| 17.05.2020 | QurAlis raises $42M in Series A round to develop therapies f... | Carbon Health
Headquarters: San Francisco
Funding type: Series B1
Amount: $28 million
Carbon Health,... | medcitynew... |
| 13.05.2020 | QurAlis Collects $42M in Series A |
CAMBRIDGE, MA, QurAlis Corporation announced the raise of a $42 million Series A financing.
>&... | vcnewsdail... |
| 13.05.2020 | QurAlis raises $42 Million Series A Financing to Develop New... | Funding led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery Fund | svhealthin... |
| 13.05.2020 | QurAlis Raises $42M in Series A Financing | QurAlis Corporation, a Cambridge, Mass.-based biotech company focused on developing precision therap... | finsmes.co... |
| 13.05.2020 | QurAlis Raises $42M Series A Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing prec... | citybizlis... |
| 20.11.2018 | Term Sheet — Tuesday, November 20 | A CRYPTO COLLAPSE
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see... | fortune.co... |
| 20.11.2018 | Cambridge-Based QurAlis Raises $5.5 Million To Develop Thera... | Cambridge, Massachusetts-based biotech company QurAlis announced that it has raised $5.5 million to ... | pulse2.com... |
| 19.11.2018 | ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ... | Neurodegenerative disease startup QurAlis has extended the seed round it first announced this past A... | fiercebiot... |
| 19.11.2018 | QurAlis Raises $5.5M in Seed Funding | QurAlis Corporation, a Cambridge, MA-based biotech company focused on developing precision therapeut... | finsmes.co... |
| 19.11.2018 | QurAlis Raises $5.5 Million Seed Round | CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company focused on developing prec... | citybizlis... |
| 19.11.2018 | ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ... | Neurodegenerative disease startup QurAlis has extended the seed round it first announced this past A... | fiercebiot... |
| 19.11.2018 | QurAlis Raises $5.5M Seed Round |
CAMBRIDGE, MA, QurAlis announced the raising of a seed extension, bringing the total funding to da... | vcnewsdail... |
| 12.09.2018 | Startup Spotlight: Pfizer taps two neuroscience startups for... | Just months after Pfizer slashed hundreds of jobs in its own neuroscience R&D program, the pharm... | statnews.c... |
| 05.04.2018 | Amgen backs Harvard professors’ ALS startup QurAlis | QurAlis has raised seed funding from a syndicate featuring Amgen Ventures. The startup will use the ... | fiercebiot... |
| 05.04.2018 | QurAlis Raises Seed Funding | QurAlis Corporation, a Cambridge, MA-based new private biotech company focused on developing precisi... | finsmes.co... |
| 05.04.2018 | Amgen backs Harvard professors’ ALS startup QurAlis
W h i t... | QurAlis has raised seed funding from a syndicate featuring Amgen Ventures. The startup will use the ... | fiercebiot... |
| 04.04.2018 | Harvard big-shots Kevin Eggan and Clifford Woolf launch AL... | A group of well-known Harvard professors has launched a new ALS spinout to take on research Big... | endpts.com... |
| - | QurAlis raises $42M in Series A round to develop therapies f... | Healthcare startups that have raised funding rounds this week include a firm developing a way to dia... | medcitynew... |
| - | QurAlis | “QurAlis is a biotech company focused on developing precision medicines for amyotrophic lateral scle... | fastfounde... |
